Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
Volume 0.53M
Average 0.38M
ALMR Net Income
Bottom-line profit after all expenses, interest, and taxes.
Alamar Biosciences, Inc.NASDAQ: ALMR
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income of -$13.2M in Q2 FY2026
Q2 FY2026 net income was -$13.2M.
Context
- Net income amounted to 40.2% of revenue in FY2025.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$93.26M (-212.8%) for the fiscal year ending Dec 2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$13.2M+38.1% QoQ
- Last fiscal yearDec 2025
- -$29.82M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | -212.8% | — |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (29.82M) USD
- Year-over-year change
- —
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (29.82M) | — |
Net Income vs competitors
How ALMR compares with its peers on the latest reported figures
- ALMR's FY2025 net income of -$29.82M is the 2nd highest of the 9 companies compared; the peer median is -$82.29M.
- Net income amounts to 40.2% of revenue for ALMR, versus a peer median of 80.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $171.97M | +120.5% | -13.9% | 14.0% | |
ALMRAlamar Biosciences, Inc. | FY2025 | -$29.82M | — | — | 40.2% |
| LTM Mar 2026 | -$57.09M | +16.9% | — | — | |
| LTM Sep 2026 | -$67.08M | +12.1% | — | 10.8% | |
| LTM Mar 2026 | -$70.49M | +17.9% | — | 468.7% | |
| LTM Mar 2026 | -$94.08M | +29.1% | — | 109.1% | |
| LTM Mar 2026 | -$103.82M | -3.1% | — | 5605.9% | |
| LTM Mar 2026 | -$128.58M | +80.5% | — | 80.3% | |
| LTM Sep 2026 | -$130.2M | -67.6% | — | 28.3% | |
| Peer median (excluding ALMR) | -$82.29M | +17.4% | -13.9% | 80.3% | |
Competitors are the stored peer set for ALMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 74.21M |
| Cost of Revenue | 32.51M |
| Gross Profit | 41.71M |
| Gross Margin | 56.2% |
| Research & Development | 37.47M |
| Selling, General & Admin | 35.57M |
| Operating Expenses | 73.04M |
| Depreciation & Amortization | 3.86M |
| EBITDA | (24.89M) |
| EBITDA Margin | -33.5% |
| Operating Income | (31.33M) |
| Operating Margin | -42.2% |
| Interest Income | 2.16M |
| Interest Expense | 401K |
| Other Income / Expenses | 2.18M |
| Income Before Tax | (29.15M) |
| Pre-Tax Margin | -39.3% |
| Income Tax Expense | 665K |
| Net Income | (29.82M) |
| Net Margin | -40.2% |
| EPS (Basic) | (0.45) |
| EPS (Diluted) | (0.45) |
| Weighted Avg Shares | 66.52M |
| Weighted Avg Shares (Diluted) | 66.52M |
Alamar Biosciences, Inc.
NASDAQ:ALMR
Intrinsic Alpha fair value
Locked
Current Price
$30.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.